Independent High Risk AGP Panel

The Independent Panel on High Risk Aerosol Generating Procedures (AGP) is a UK-wide, independent, non-executive expert advisory panel that provides practical and scientific advice to the Chief Medical Officers (CMOs) for England, Scotland, Wales and Northern Ireland on specific high risk AGPs in the context of the coronavirus (COVID-19) pandemic.

The Independent High Risk AGP Panel has now concluded its work. A final activity update can be found here.

Role of group

The Independent Panel on High Risk Aerosol Generating Procedures (AGPs) will assess the evidence for complex and unclear cases, where there are differing views on defining AGPs, taking into account the potential route of transmission and making recommendations for the appropriate classification.

Membership

Please see meeting summaries for details of members’ and co-opted experts’ periods of service.

Panel membership:

Prof Jacqui Reilly (Chair)
Prof Jennie Wilson (Deputy Chair)
Prof Alistair Leanord
Dr Cariad Evans
Dr David Farren
Dr David Jenkins
Ms Ema Swingwood
Dr Gail Carson
Dr James Tysome
Prof Martin Llewelyn
Ms Melanie Burden
Dr Nick Murch
Dr Shaun Fitzgerald

Co-opted expertise:

Dr Adam Boise
Dr Alexandra Freeman

Terms of reference

Independent High Risk AGP Panel: terms of reference (PDF, 349 KB, 7 pages)

Members’ interest

Independent High Risk AGP Panel: declarations of interest (PDF, 388 KB, 3 pages)

Panel Meeting

Having released its summary of recommendations on medical procedures that do not currently meet the threshold for consideration as an aerosol generating procedure (AGP), the Independent High Risk AGP Panel has now concluded its work. A record of panel meetings during the panels period of activity can be found as meeting summaries.

Summaries of meetings

Read summaries of AGP meetings

Publications

Independent High Risk AGP Panel: summary of recommendations

Contact details

As the Independent High Risk AGP Panel has now concluded its work, all requests relating to aerosol generating procedures are to be considered by the COVID-19 UK Infection Prevention and Control (IPC) cell and the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG).